More than one million people have used Thomson Healthcare (NYSE: TOC; TSX: TOC) Profiler treatment option tools to help make treatment decisions for cancer, heart disease and lung disease. "When you consider more than 20 million people are diagnosed with cancer, heart disease or lung disease each year, this is not the kind of milestone one celebrates," said Alicia Moffat, Thomson Healthcare's vice president of Web operations. 
The U.S. Food and Drug Administration notified the public that Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B) have been linked in some cases to adverse reactions, including respiratory failure and death, following treatment of a variety of conditions using a wide range of doses. 
Manhattan Research, a leader in syndicated research and marketing services for the health and pharmaceutical industry, today revealed the top pharmaceutical branded product websites ranked by offline requests by U.S. adult consumers. The product site rankings are based on the comprehensive
online consumer research study with 5,112 U.S. adults titled ePharma Consumer® v7.0: The Future of Integrated DTC Marketing.